# VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM

> **NCT03149575** · PHASE3 · TERMINATED · sponsor: **DelMar Pharmaceuticals, Inc.** · enrollment: 2 (actual)

## Conditions studied

- Glioblastoma Multiforme
- Glioblastoma
- Glioma
- GBM
- Brain Cancer

## Interventions

- **DRUG:** VAL-083, Dianhydrogalactitol
- **DRUG:** Physician's Choice of Salvage Therapy - temozolomide
- **DRUG:** Physician's Choice of Salvage Therapy - lomustine
- **DRUG:** Physician's Choice of Salvage Therapy - carboplatin

## Key facts

- **NCT ID:** NCT03149575
- **Lead sponsor:** DelMar Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-27
- **Primary completion:** 2019-05-31
- **Final completion:** 2019-08-31
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Change in clinical development plan
- **Last updated:** 2025-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03149575

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03149575, "VAL-083 Phase 3 Study in Temozolomide-Avastin (Bevacizumab) Recurrent GBM". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03149575. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*